XOMA Corp. regulatory update

XOMA (Berkeley, Calif.) received its first U.S. patent relating to the manufacturing process of Bactericidal/Permeability-Increasing Protein (BPI). U.S. Patent No. 5,439,807 covers a method for the recombinant manufacture of BPI and other endotoxin-binding proteins such as lipopolysaccharide-binding protein. The method improves production yields of XOMA's lead product, Neuprex (rBPI21), which is in Phase II trials for several indications. ...